4’-氰基联苯-3-羧酸 | 149506-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4’-氰基联苯-3-羧酸
• 中文别名: 4'-氰基-3-联苯甲酸
• 英文名称: 4'-cyano-[1,1'-biphenyl]-3-carboxylic acid
• 英文别名: 4′-cyanobiphenyl-3-carboxylic acid；4'-cyanobiphenyl-3-carboxylic acid；4'-Cyano-3-biphenylyl carboxylic acid；4'-Cyano-biphenyl-3-carboxylic acid；3-(4-cyanophenyl)benzoic acid
• CAS: 149506-93-4
• 化学式: C₁₄H₉NO₂
• 分子量: 223.231
• InChiKey: WLUGFHVTVXLVFB-UHFFFAOYSA-N

物化性质

• 沸点：
  463.0±38.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4’-Cyanobiphenyl-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
P264: Wash thoroughly after handling
P270: Do not eat, drink or smoke when using this product
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 4’-Cyanobiphenyl-3-carboxylic acid
CAS number: 149506-93-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H9NO2
Molecular weight: 223.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4’-氰基联苯-3-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride

  摘要：

  对核准抗病毒药物产生耐药性的流感病毒日益增多,这凸显了开发新型抗流感药物的必要性。本文描述了六亚甲基氨氯吡嗪(HMA)衍生物的功能特性,它们能抑制A型流感M2离子通道的野生型和金刚烷胺耐药型。例如, 6-( 唑戊吡嗪-1-吡啦达)-N-甲甲喷达吡嗪-氨酸胺(9)对金刚烷胺敏感的M2离子通道电流的抑制效力比金刚烷胺或HMA高3至6倍(IC50分别为0.2、0.6和1.3μM)。化合物9与金刚烷胺竞争抑制M2, 分子对接模拟显示9结合在金刚烷胺结合位点的重叠处。此外, 二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(27)既对敏感型M2有效, 也对编码丝氨酸31突变为天冬酰胺(S31N)的耐药型M2变种有效, 且效力优于金刚烷胺和HMA(IC50分别为0.6μM和4.4μM)。虽然9抑制了编码野生型M2的流感病毒的体外复制(EC50=2.3μM), 但27和二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(26)更倾向于抑制编码M2(S31N)的病毒(各自的EC50分别为18.0和1.5μM)。这一发现表明,可以设计HMA衍生物来抑制金刚烷胺耐药的病毒。我们的研究强调了HMA衍生物作为耐药性流感M2离子通道抑制剂的潜力。

  DOI：

  10.1124/mol.115.102731
• 作为产物：
  描述：

  对氨基苯腈 在 2-双环己基膦-2',6'-二甲氧基联苯 、 盐酸 、 palladium diacetate 、 potassium carbonate 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.58h， 生成 4’-氰基联苯-3-羧酸
  参考文献：
  名称：

  Sequential One-Pot Access to Molecular Diversity through Aniline Aqueous Borylation

  摘要：

  On the basis of our recently reported aniline aqueous borylation, molecular diversity was achieved in a one-pot process by combining other reactions such as esterification, Suzuki-Miyaura coupling, hydrogenolysis, or Petasis borono-Mannich.

  DOI：

  10.1021/jo501665e

文献信息

• [EN] AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES AMIDE DE 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-D]PYRIMIDINONES, AINSI QUE LEUR PREPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2006024487A1

  公开（公告）日：2006-03-09

  The present invention relates to novel amide derivatives of 7-amino-3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I).

  本发明涉及7-氨基-3-苯基二氢嘧啶[4,5-d]嘧啶酮的新型酰胺衍生物，其制造工艺，含有它们的药物及其制造，以及这些化合物作为药物活性剂的使用。本发明的衍生物是通用公式（I）的新化合物。
• Amide Derivatives of 3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents
  申请人：Engh Richard

  公开号：US20070232611A1

  公开（公告）日：2007-10-04

  The present invention relates to novel amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I).

  本发明涉及3-苯基二氢嘧啶并[4,5-d]嘧啶酮的新酰胺衍生物，以及其制备方法、含有它们的药物、以及这些化合物作为药用活性剂的用途。本发明的衍生物是一般式(I)的新化合物。
• Cyclic imino derivatives and pharmaceutical compositions containing them
  申请人：Karl Thomae GmbH

  公开号：US05541343A1

  公开（公告）日：1996-07-30

  The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.

  这项发明涉及具有有价值的药理特性，特别是对细胞聚集具有抑制作用的环亚胺化合物，包含这些化合物的药物组合物以及制备它们的方法。
• NOVEL COMPOUNDS
  申请人：HEIMANN Annekatrin

  公开号：US20130158042A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R 1 , R 2 , R 3 , R 4 , Q have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。
• PROTEASOME INHIBITORS AND USES THEREOF
  申请人：CORNELL UNIVERSITY

  公开号：US20180282317A1

  公开（公告）日：2018-10-04

  The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R, R 1 -R 5 , k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由具有以下式（I）的化合物表示，其中取代基R，R1-R5，k，m，n和q如本文所定义。这些化合物用于治疗癌症、免疫紊乱、自身免疫紊乱、神经退行性疾病、炎症性疾病、传染病，或为移植的器官或组织提供免疫抑制。